Skip to content

Net Income at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$2.68B+9.0%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$1.03B+59.6%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$3.78M+132%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
-$99.11M-11.0%
Beam Therapeutics logo
Beam TherapeuticsBEAM
-$94.32M+12.9%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
-$37.1M+10.0%

Segments

By segment

See full
Key Measure Of Segment Profit Or Loss-$63.5M-86.3%

Other financials

Income statement

See full
Operating income-$69.5M-74.0%
EPS (diluted)-$1.65-61.8%

Balance sheet

See full
Cash & equivalents$88.9M-27.5%
Total debt$31.1M+1.4%
Total equity$688.4M+4.3%
Total assets$750.2M+5.8%

Cash flow

See full
Operating cash flow-$62.2M-50.4%
CapEx--100%
Free cash flow-$62.2M-47.4%

Valuation

See full
Market cap$2.69B+42.2%
Enterprise value$2.63B+46.7%

Returns & leverage

See full
Return on equity-35.8%+41.3pp
Debt / equity0.0×
Current ratio24×-13.6×

Where this comes from

Reported directly by Disc Medicine in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The official record: Disc Medicine’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Disc Medicine's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Disc Medicine's net income?
Disc Medicine (IRON) reported net income of -$63.5M in Q1 2026.
How has Disc Medicine's net income changed year-over-year?
Disc Medicine's net income decreased by 86.3% year-over-year, from -$34.09M to -$63.5M.
What is the long-term trend for Disc Medicine's net income?
Over 3 years (2022 to 2025), Disc Medicine's net income has grown at a 65.5% compound annual growth rate (CAGR), from -$46.83M to -$212.18M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.